GlaxoSmithKline - Vir Biotech's Antibody COVID-19 Treatment Wins CHMP's Positive Scientific Opinion

• The European Medicines Agency’s advisory group, Committee for Human Medicinal Products (CHMP), has concluded that GlaxoSmithKline plc (NYSE: GSK) and Vir Biotechnology Inc (NASDAQ: VIR) antibody COVID-19 treatment, sotrovimab, can be used.

• The opinion covers confirmed COVID-19 in adults and adolescents who don’t require supplemental oxygen therapy and are at risk of progressing to severe COVID-19.

• EMA said an interim analysis of the infusion indicated that sotrovimab reduced the risk of hospitalization for more than 24 hours or death by 85% compared with placebo.

• Hospitalization for more than 24 hours or death occurred in 1% (3 out of 291) of patients who received sotrovimab and 7% (21 out of 292) of those who received placebo.

• The companies also submitted an emergency use authorization application for the mAb to the FDA, and Health Canada is also reviewing it.

• Price Action: VIR shares are down 0.09% at $45.11, and GSK stock is down 0.40% at 38.87 during the market session on the last check Friday.

See more from Benzinga

• Click here for options trades from Benzinga

• GSK Exits Respiratory Partner Innoviva In 2M Deal

• GlaxoSmithKline-Medicago's COVID-19 Vaccine Candidate Elicit Strong Immune Response

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.